Gilead Sciences, Inc.
(NASDAQ : GILD)

( )
GILD After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -0.59%160.430.0%$1785.47m
OCGNOcugen, Inc. -1.71%8.600.0%$1110.21m
BNTXBioNTech SE 2.87%198.300.0%$880.73m
AMGNAmgen, Inc. 0.40%252.381.3%$741.37m
NVAXNovavax, Inc. 6.43%140.1679.8%$613.90m
SNSSSunesis Pharmaceuticals, Inc. 6.90%8.210.7%$573.91m
GILDGilead Sciences, Inc. 0.79%69.071.0%$509.27m
REGNRegeneron Pharmaceuticals, Inc. 1.38%523.732.7%$424.50m
ALXNAlexion Pharmaceuticals, Inc. 0.73%174.752.0%$370.86m
VRTXVertex Pharmaceuticals, Inc. -0.34%216.351.9%$297.96m
ILMNIllumina, Inc. -0.41%379.483.5%$290.64m
BIIBBiogen, Inc. 0.07%280.401.7%$268.65m
VXRTVaxart, Inc. -2.72%6.430.0%$244.65m
CRSPCRISPR Therapeutics AG 2.42%109.220.6%$178.48m
BNGOBionano Genomics, Inc. 3.70%5.600.0%$175.20m

Company Profile

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.